PerkinElmer (PKI) says it's completed the acquisition of Shanghai Haoyuan Biotech, a China-based...

|By:, SA News Editor

PerkinElmer (PKI) says it's completed the acquisition of Shanghai Haoyuan Biotech, a China-based infectious disease diagnostics company, for $38M in cash plus future consideration based on the achievement of revenue-based targets. PKI says the deal should be immaterial to adjusted earnings for the remainder of 2012 and 2013 and accretive beginning in 2014.